Leukocare specializes in biopharmaceutical formulation development, operating at the interface of drug substance and drug product development. The company combines formulation expertise with bioinformatics and AI, using a library of up to 100 regulatory excipients and rational development tools. Its approach employs statistical software, self-learning algorithms and design of experiment (DoE) matrices to create stabilizing formulations tailored to drug products. Leukocare’s formulations target biologics & biosimilars, vaccines & viral vectors, and biofunctionalized devices. The company opened US development laboratories and offices in Milford, Massachusetts in January 2021. Proceeds from the recent financing will be used to accelerate its US expansion, bolster expertise in viral vector, vaccine and mRNA formulation, and expand its bioinformatics capabilities. Leukocare is a clinical-stage biotechnology company based in Munich that develops Stabilizing and Protecting Solutions (SPS®) for proteins and other biologics. Led by CEO Michael Scholl, the company focuses on formulation technologies to stabilize vaccines, biopharmaceuticals and combination devices. The company recently closed a growth financing round of undisclosed amount to advance its programs. As part of its strategy, Leukocare plans to use the funds to conduct market access activities for a number of development projects based on its SPS® platform. No operating metrics or revenue figures were disclosed in the article.

Total raised

$18M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2021